Inhibition of baicalin on metabolism of phenacetin, a probe of CYP1A2, in human liver microsomes and in rats

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Gao, Na ^a   Qi, Bing ^a   Liu, Fang Jun ^b   Fang, Yan ^a   Zhou, Jun ^a   Jia, Lin Jing ^a   Qiao, Hai Ling ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b Unified Supply Center The 89th Hospital of Chinese People's Liberation Army   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BAICALIN; CYTOCHROME P450 1A2; PHENACETIN; FLAVONOID; PRIMER DNA;

ADULT; AGED; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; ANIMAL; DRUG EFFECTS; GENETICS; IC50; KINETICS; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; SPRAGUE DAWLEY RAT;

ADULT; ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 CYP1A2; DNA PRIMERS; FEMALE; FLAVONOIDS; GENOTYPE; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PHENACETIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84896364287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089752     Document Type: Article

References (31)

1. Foster BC, Arnason JT, Briggs CJ (2005) Natural health products and drug disposition. Annu Rev Pharmacol Toxicol 45: 203-226. (Pubitemid 40261803)
2. Soligard HT, Bratlid D, Cao C, Liang A, Nilsen OG (2011) Displacement of bilirubin from albumin in plasma from jaundiced newborns. An in vitro study of purified Chinese herbal constituents and sulfisoxazole. Phytother Res 25: 1068-1072.
3. Elvin-Lewis M (2001) Should we be concerned about herbal remedies. J Ethnopharmacol 75: 141-164.
4. Ernst E (1998) Harmless herbs? A review of the recent literature. Am J Med 104: 170-178.
5. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34: 83-448.
6. Usia T, Watabe T, Kadota S, Tezuka Y (2005) Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci 76: 2381-2391. (Pubitemid 40313425)
7. Yang X, Yang J, Zou H (2013) Baicalin inhibits IL-17-mediated joint inflammation in murine adjuvant-induced arthritis. Clin Dev Immunol 2013: 268065.
8. Akao T, Sato K, He JX, Ma CM, Hattori M (2013) Baicalein 6-O-β-D-glucopyranuronoside is a main metabolite in the plasma after oral administration of baicalin, a flavone glucuronide of scutellariae radix, to rats. Biol Pharm Bull 36: 748-753.
9. Tian X, Cheng ZY, He J, Jia LJ, Qiao HL (2013) Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Chem Biol Interact 203: 522-529.
10. Gao N, Zou D, Qiao HL (2013) Concentration-dependent inhibitory effect of Baicalin on the plasma protein binding and metabolism of chlorzoxazone, a CYP2E1 probe substrate, in rats in vitro and in vivo. PLoS One 8: e53038.
11. Gao N, Fang Y, Qi B, Jia LJ, Jin H, et al. (2013) Pharmacokinetic changes of unbound theophylline are due to plasma protein binding displacement and CYP1A2 activity inhibition by baicalin in rats. J Ethnopharmacol 150: 477-484.
12. Tian X, Cheng ZY, Jin H, Gao J, Qiao HL (2013) Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats. Evid Based Complement Alternat Med 2013: 179643.
13. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423. (Pubitemid 24229655)
14. Or PM, Lam FF, Kwan YW, Cho CH, Lau CP, et al. (2012) Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms. Phytomedicine 19: 535-544.
15. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31: 815-832. (Pubitemid 36759050)
16. Zhu Q, Liao J, Xie L, Wang GJ, Liu XD (2009) Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica 39: 293-301.
17. Hu L, Xu W, Zhang X, Su J, Liu X, et al. (2010) In-vitro and in-vivo evaluations of cytochrome P450 1A2 interactions with nuciferine. J Pharm Pharmacol 62: 658-662.
18. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, et al. (1999) Genetic polymorphism in the 59-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125: 803-808. (Pubitemid 29192503)
19. Sachse C, Brockmöller J, Bauer S, Roots I (1999) Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47: 445-449. (Pubitemid 29161279)
20. Court MH, Greenblatt DJ (1997) Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochem Pharmacol 53(7): 1041-1047. (Pubitemid 27224285)
21. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
22. Saebø M, Skjelbred CF, Brekke Li K, Bowitz Lothe IM, Hagen PC, et al. (2008) CYP1A2 164 A->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas. Anticancer Res 28: 2289-2295.
23. Ju WZ, Liu F, Wu T, Xia XY, Tan HS, et al. (2007) Simultaneous determination of baicalin and chlorogenic acid in human plasma by UPLC-MS/MS. Yao Xue Xue Bao 42: 1074-1077.
24. Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, et al. (2004) Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57: 487-494. (Pubitemid 38519654)
25. Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T (2006) Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol 61: 309-314. (Pubitemid 43382630)
26. Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher CM, et al. (2005) CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol 68: 644-651. (Pubitemid 41206018)
27. Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS (2008) Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 36: 1242-1248. (Pubitemid 351929306)
28. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41: 89-295.
29. Han XM, Chen XP, Wu QN, Jiang CH, Zhou HH (2000) G-2964A and C734A genetic polymorphisms of CYP1A2 in Chinese population. Acta Pharmacol Sin 21: 1031-1034.
30. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, et al. (1993) Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3(5): 239-249. (Pubitemid 23333093)
31. Lucas D, Berthou F, Dréano Y, Lozac'h P, Volant A, et al. (1993) Comparison of levels of cytochromes P-450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical liver samples. Alcohol Clin Exp Res17: 900-905. (Pubitemid 23249043)